EP1150701A4 - Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung - Google Patents

Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung

Info

Publication number: EP1150701A4
Authority: EP; European Patent Office
Prior art keywords: methods; same; homing pro; apoptotic conjugates; apoptotic
Prior art date: 1999-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP00911617A

Other languages

English (en)

French (fr)

Other versions

EP1150701A2 (de

Inventor

H Michael Ellerby

Dale E Bredesen

Renata Pasqualini

Erkki I Ruoslahti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanford Burnham Prebys Medical Discovery Institute

Original Assignee

Sanford Burnham Prebys Medical Discovery Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-22

Filing date

2000-01-21

Publication date

2003-03-26

2000-01-21 Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute

2001-11-07 Publication of EP1150701A2 publication Critical patent/EP1150701A2/de

2003-03-26 Publication of EP1150701A4 publication Critical patent/EP1150701A4/de

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

EP00911617A 1999-01-22 2000-01-21 Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung Ceased EP1150701A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23590299A	1999-01-22	1999-01-22
US235902		1999-01-22
PCT/US2000/001602 WO2000042973A2 (en)	1999-01-22	2000-01-21	Homing pro-apoptotic conjugates and methods of using same

Publications (2)

Publication Number	Publication Date
EP1150701A2 EP1150701A2 (de)	2001-11-07
EP1150701A4 true EP1150701A4 (de)	2003-03-26

Family

ID=22887331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00911617A Ceased EP1150701A4 (de)	1999-01-22	2000-01-21	Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung

Country Status (5)

Country	Link
EP (1)	EP1150701A4 (de)
JP (1)	JP4531267B2 (de)
AU (1)	AU770381B2 (de)
CA (1)	CA2359633A1 (de)
WO (1)	WO2000042973A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003520808A (ja) *	2000-01-21	2003-07-08	ザバーナムインスティチュート	プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド
AU781951B2 (en) *	2000-02-02	2005-06-23	Transgene S.A.	Targeting peptides
ATE415414T1 (de)	2000-09-11	2008-12-15	Pasteur Institut	Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren
US20030077826A1 (en) *	2001-02-02	2003-04-24	Lena Edelman	Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US8507445B2 (en)	2001-09-07	2013-08-13	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) *	2002-08-30	2010-03-02	The Board Of Regents Of The University Of Texas System	Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7192921B2 (en)	2001-11-08	2007-03-20	The Burnham Institute	Peptides that home to tumor lymphatic vasculature and methods of using same
WO2003040693A2 (en)	2001-11-08	2003-05-15	The Burnham Institute	Peptides that home to tumor lymphatic vasculature and methods of using same
EP1346729A1 (de) *	2002-03-19	2003-09-24	Cardiovascular Research Institute Maastricht	Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
AU2003242506A1 (en) *	2002-07-12	2004-02-02	Novo Nordisk A/S	Tf antagonist
JP4524359B2 (ja) *	2003-03-24	2010-08-18	学校法人日本医科大学	癌に特異的に作用する細胞死誘導融合遺伝子及びその遺伝子産物
GB0312309D0 (en)	2003-05-29	2003-07-02	Gaslini Children S Hospital G	Targeted liposome
US7598341B2 (en)	2003-10-31	2009-10-06	Burnham Institue For Medical Research	Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2005094383A2 (en) *	2004-03-31	2005-10-13	Buck Institute	Hunter-killer peptides and methods of use
WO2006029343A2 (en) *	2004-09-07	2006-03-16	The Burnham Institute	Peptides that selectively home to heart vasculature and related conjugates and methods
AU2006320327A1 (en) *	2005-12-01	2007-06-07	Duke University	Compounds and methods for inhibiting apoptosis
FI121959B (fi) *	2008-05-09	2011-06-30	Pirjo Laakkonen	Aivokasvaimiin hakeutuva peptidi
EP2414389A1 (de) *	2009-04-01	2012-02-08	Schmidt-Wolf, Ingo	Auf tumore zielende peptide und therapeutische und diagnostische zusammensetzungen, die die peptide enthalten
CA2795289A1 (en) *	2010-04-08	2011-10-13	Sanford-Burnham Medical Research Institute	Methods and compositions for enhanced delivery of compounds
US10669311B2 (en)	2015-04-23	2020-06-02	Sanford Burnham Prebys Medical Discovery Institute	Targeted delivery system and methods of use therefor
EP3405209B1 (de) *	2016-01-19	2021-05-26	The University Of Western Australia	Neuartige biomolekülkonjugate und verwendungen davon
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11021529B2 (en)	2017-03-03	2021-06-01	Massachusetts Institute Of Technology	Antimicrobial constructs and uses thereof
CN108314741B (zh) *	2018-03-22	2021-08-03	中国人民解放军第四军医大学	一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
JP2023523039A (ja) *	2020-04-22	2023-06-01	オンコヴォリューションエル・エル・シー	ペプチド白金錯体およびその使用方法
CN112830975B (zh) *	2021-02-02	2023-03-10	西南交通大学	α-螺旋构象稳定的促凋亡双环多肽及制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789542A (en) *	1994-04-22	1998-08-04	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Amphipathic peptides
US5773292A (en) *	1995-06-05	1998-06-30	Cornell University	Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
ATE214075T1 (de) *	1996-05-31	2002-03-15	Health Research Inc	Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
DE69734887T2 (de) *	1996-09-10	2006-08-24	The Burnham Institute, La Jolla	Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
EP1062232B1 (de) *	1998-03-13	2008-09-10	The Burnham Institute	Zielsuchende verbindungen für verschiedene organe und gewebe

2000
- 2000-01-21 AU AU33486/00A patent/AU770381B2/en not_active Ceased
- 2000-01-21 EP EP00911617A patent/EP1150701A4/de not_active Ceased
- 2000-01-21 JP JP2000594432A patent/JP4531267B2/ja not_active Expired - Fee Related
- 2000-01-21 CA CA002359633A patent/CA2359633A1/en not_active Abandoned
- 2000-01-21 WO PCT/US2000/001602 patent/WO2000042973A2/en not_active Application Discontinuation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAVADPOUR MARYAM M ET AL: "De novo antimicrobial peptides with low mammalian cell toxicity.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 16, 1996, pages 3107 - 3113, XP002228388, ISSN: 0022-2623 *
See also references of WO0042973A3 *

Also Published As

Publication number	Publication date
AU3348600A (en)	2000-08-07
WO2000042973A3 (en)	2000-09-28
WO2000042973A2 (en)	2000-07-27
CA2359633A1 (en)	2000-07-27
JP4531267B2 (ja)	2010-08-25
EP1150701A2 (de)	2001-11-07
AU770381B2 (en)	2004-02-19
JP2002535258A (ja)	2002-10-22

Publication	Publication Date	Title
EP1150701A4 (de)	2003-03-26	Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung
IL183948A (en)	2010-11-30	Peg-urate oxidase conjugates and use thereof
HRP20060251B1 (hr)	2016-08-12	Supstituirani oksazolidinoni i njihova uporaba
AU8026600A (en)	2001-04-30	Brachytherapy instrument and methods
AP2002002505A0 (en)	2002-06-30	Novel compostition and use
AU8967998A (en)	1999-09-15	Antibiotic-ligand conjugates and methods of use thereof
IL148247A (en)	2014-01-30	Vaccine and its uses
GB9924351D0 (en)	1999-12-15	Immunomodulation methods and compositions
EP1183030A4 (de)	2007-11-21	Verfahren zur herstellung und ihre verwenung von n-desmethylzopiclone
HUP0301076A3 (en)	2004-06-28	Linezolid-crystal form ii and preparation thereof
IL146842A0 (en)	2002-07-25	Polymer conjugates of hedgehog proteins and uses
EP1194147A4 (de)	2002-10-09	Arylthiazolidindion- und aryloxazolidinderivate
AUPQ342599A0 (en)	1999-11-04	Conjugates and uses thereof
HK1040486A1 (zh)	2002-06-14	脂肪酸-抗癌共軛和其用途
EP1147213A4 (de)	2003-08-20	RGS-ENTHALTENDE MOLEKüLE UND DEREN VERWENDUNGEN
GB0023323D0 (en)	2000-11-08	Arylhydantoin derivatives and uses thereof
IL131707A0 (en)	2001-03-19	Acetylcholinesterase-derived peptides and uses thereof
EG22491A (en)	2003-03-31	Rest-breaking composition and use thereof
GB9922135D0 (en)	1999-11-17	Compositions and uses
IL131719A0 (en)	2001-03-19	Iren protein its preparation and use
EP1229913A4 (de)	2005-01-19	Substituierte 1-benzazepine und dessen derivate
GB0318112D0 (en)	2003-09-03	›-Secretase enzyme compositions and methods
AU2136401A (en)	2001-06-25	P450rai-2 and related proteins
AU6084598A (en)	1998-09-18	Antibiotic-ligand conjugates and methods of use thereof
AU6204400A (en)	2001-01-31	Novel kinases and uses thereof

Legal Events

Date	Code	Title	Description
2001-09-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-11-07	17P	Request for examination filed	Effective date: 20010806
2001-11-07	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-11-14	RIN1	Information on inventor provided before grant (corrected)	Inventor name: PASQUALINI, RENATA Inventor name: RUOSLAHTI, ERKKI, I. Inventor name: ELLERBY, H., MICHAEL Inventor name: BREDESEN, DALE, E.
2001-11-28	RIN1	Information on inventor provided before grant (corrected)	Inventor name: RUOSLAHTI, ERKKI, I. Inventor name: PASQUALINI, RENATA Inventor name: ELLERBY, H., MICHAEL Inventor name: BREDESEN, DALE, E.
2002-03-13	RIN1	Information on inventor provided before grant (corrected)	Inventor name: BREDESEN, DALE, E. Inventor name: ELLERBY, H., MICHAEL Inventor name: PASQUALINI, RENATA Inventor name: RUOSLAHTI, ERKKI, I.
2003-03-19	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61K 39/00 B Ipc: 7A 61K 38/00 A Ipc: 7C 07K 5/00 B Ipc: 7C 07K 4/00 B Ipc: 7C 07K 2/00 B Ipc: 7C 07K 17/00 B Ipc: 7C 07K 14/00 B Ipc: 7A 61K 47/48 B Ipc: 7A 61K 39/02 B Ipc: 7A 61K 38/04 B Ipc: 7C 07K 16/00 B
2003-03-26	A4	Supplementary search report drawn up and despatched	Effective date: 20030206
2004-08-04	17Q	First examination report despatched	Effective date: 20040617
2006-11-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2006-12-27	18R	Application refused	Effective date: 20060820
2007-08-08	RIN1	Information on inventor provided before grant (corrected)	Inventor name: BREDESEN, DALE, E. Inventor name: PASQUALINI, RENATA Inventor name: RUOSLAHTI, ERKKI, I. Inventor name: ELLERBY, H., MICHAEL